Arctoris is a tech-enabled biopharma platform company founded and headquartered in Oxford, UK. Its US operations are based in Boston and its Asia-Pacific operations are based in Singapore. Arctoris combines robotics and data science with a world-class team for small molecule and biologics discovery.
Ulysses®, Arctoris’ unique technology platform, enables the company and its partners to conduct their R&D significantly faster, and with considerably improved data quality and depth.
Bringing together the expertise of seasoned biotech and pharma veterans with its proprietary technologies, Arctoris leads to higher success rates and an accelerated progression of programmes towards the clinic. Arctoris pursues an internal pipeline of assets in oncology and neuro and also collaborates with select biotech and pharma partners in the US, Europe, and Asia-Pacific.
Tom Fleming was a Royal Commission of 1851 fellow on the Enterprise Fellowships programme at the University of Oxford, and then joined the Academy’s SME Leaders programme (now known as the Shott Scale Up Accelerator). He joined EXPLORE’s first mission to Massachusetts to strengthen his connections in the life sciences ecosystem and strategise for expansion.
The EXPLORE programme and international mission to Boston helped us to bridge our network into the local biotech ecosystem that otherwise seems opaque and impenetrable. This has enabled us to effectively land and expand in Boston and access new business and investment opportunities.
EXPLORE
day international mission to the ecosystem-infocus packed with
days of expert-led workshops on industry insights centred on capital, talent, market, and intellectual property
maximum in equity-free funding to embed the programme’s learning and connections
business coaching and mentoring from international and UK advisors unmissable meetings, insights and networking opportunities
EXPLORE is an exclusive programme for Hub Members that supports up to five deep-tech entrepreneurs to increase their visibility, connections and exposure to investment in new overseas ecosystems.